NCT05280925Completed
Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment
Episodic Future Thinking to Improve Management of Type 2 Diabetes in Rural and Urban Patients: Remote Delivery and Outcomes Assessment to Increase Reach and Dissemination
Source: ClinicalTrials.gov · Last updated 26 Jun 2025
Brief summary (registry, in English)
Successful management of type 2 diabetes (T2D) requires adherence to a dietary, physical activity, and medication plan agreed upon between a patient and their healthcare providers. The lifestyle changes involved in these collaborative care plans (CCPs) often provide little to no short-term benefit and may instead be aversive (e.g., caloric restriction and physical activity). However, these changes provide critical health benefits in the future, allowing patients with T2D to halt or reverse disease progression and avoid T2D-related complications (e.g., renal disease or diabetic retinopathy). Thus, successful management of T2D requires one's present behavior to be guided by future outcomes. Unfortunately, accumulating evidence indicates that individuals with T2D and prediabetes show elevated rates of delay discounting (i.e., devaluation of delayed consequences). Moreover, high rates of delay discounting are cross-sectionally and longitudinally associated with poor treatment adherence and clinical outcomes in T2D and prediabetes. These data suggest that high rates of delay discounting prevent successful management of T2D through a mechanism in which the health benefits of lifestyle changes are too delayed to motivate behavioral change. Thus, we believe delay discounting serves as a therapeutic target in T2D, where improving participants' valuation of the future will facilitate healthy lifestyle changes and, in turn, improve T2D management. This study will conduct a randomized 24-week remote clinical trial comparing repeated measures ANOVA, with group (episodic future thinking \[EFT\]/control) and area (urban vs. rural) as between-subjects factors, and time (baseline, week 8, and week 24 assessments) as within-subjects factors in adults with type 2 diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 137 (actual)
- First submitted
- 15 Feb 2022
- Start date
- 20 Jul 2022
- Primary completion date
- 15 Jan 2025
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT05280925
What you commit to
- Study type: Interventional
- Participants enrolled: 137
- From 20 Jul 2022 to the primary completion date, 15 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- gestational diabetes
- intellectual impairment
- unmanaged comorbid psychiatric diagnosis (including eating disorders)
Other
- pregnancy or lactating
- not ambulatory
Who the study is looking for
- HbA1c greater than or equal to 7.7%
- from urban or rural area
- body mass index greater than or equal to 30
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fralin Biomedical Research Institute at VTC Coordinator of this site? Confirm its status | Roanoke | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.